Abstracts tagged "Adult-onset Still’s disease"

Abstract Number: 1242 • 2014 ACR/ARHP Annual Meeting
Switching Biologic Agents in Refractory Adult-Onset Still’s Disease: Efficacy and Safety in a Cohort of 20 Patients at a Single Referral Center
Giulio Cavalli¹, Stefano Franchini¹, Corrado Campochiaro¹, Elena Baldissera², Lorenzo Dagna³ and Maria Grazia Sabbadini³, ¹Internal Medicine and Clinical Immunology, Vita-Salute San Raffaele University, Milan, Italy, ²Clinical immunopathology and advanced medical therapeutics, San Raffaele Scientific Institute, Milan, Italy, ³Internal Medicine and Clinical Immunology, Vita-Salute San Raffaele University, Milano, Italy
Background/Purpose No data is available on the long-term clinical outcome of Adult-Onset Still's Disease (AOSD) patients treated with biological drugs, nor on the efficacy and…
Abstract Number: 2028 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Biologic Agents In Adult-Onset Still’s Disease: A Long-Term Follow-Up Of 19 Patients At a Single Referral Center
Giulio Cavalli^1,2, Stefano Franchini¹, Alvise Berti¹, Corrado Campochiaro¹, Barbara Guglielmi¹, Maria Grazia Sabbadini¹, Elena Baldissera³ and Lorenzo Dagna^4,5, ¹Internal Medicine and Clinical Immunology, Vita-Salute San Raffaele University, Milan, Italy, ²San Raffaele Scientific Institute, Milan, Italy, ³Vita-Salute San Raffaele University, Milano, Italy, ⁴Vita-Salute San Raffaele University, Milan, Italy, ⁵Medicine and Clinical Immunology, San Raffaele Scientific Institute, Milan, Italy
Background/Purpose: No data comparing the long-term outcome of Adult-Onset Still’s Disease (AOSD) patients treated with different biological drugs is currently available. We evaluated the efficacy…
Abstract Number: 786 • 2013 ACR/ARHP Annual Meeting
Antibodies Against Drp-4 and Macropain Subunit C2 As a Potential Marker Of Aosd
Niklas T. Baerlecken¹, Nils Pursche², Torsten Witte³, Reinhold E. Schmidt¹, Marius Hoepfner¹, Frank Moosig⁴, Wolfgang L. Gross⁵, Eugen Feist⁶ and Dirk Foell⁷, ¹Clinical Immunology and Rheumatology, Medical University Hannover, Hannover, Germany, ²Clinical Immunology and Rheumatology, Medical University of Hannover, Hannover, Germany, ³Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, ⁴Vasculitis Clinic, Klinikum Bad Bramstedt & University Hospital of Schleswig Holstein, Bad Bramstedt, Germany, ⁵Dept of Clinical Rheumatology, Medical University at Lubeck, Lubeck, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ⁷Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany
Background/Purpose: Making the diagnosis of adult-onset Still's disease (AOSD) is mainly based on the exclusion of inflammatory, infectious and malignant diseases. There are no specific…
Abstract Number: 217 • 2013 ACR/ARHP Annual Meeting
Clinical Value Of ¹⁸f-Fluoro-Dexoxyglucose Positron Emission Tomography In Patients With Adult-Onset Still’s Disease
Hiroyuki Yamashita¹, Kazuo Kubota², Yuko Takahashi¹, Hiroshi Kaneko¹, Toshikazu Kano¹ and Akio Mimori¹, ¹Division of Rheumatic Diseases, National Center for Global Health and Medicine, Tokyo, Japan, ²Department of Radiology, National Center for Global Health and Medicine, Tokyo, Japan
AbstractBackground/Purpose: The aim of this study was to assess the usefulness of 18F-fluoro-dexoxyglucose positron emission tomography/Computed tomography (18F-FDG PET/CT) for the diagnosis or the evaluation…
Abstract Number: 2250 • 2012 ACR/ARHP Annual Meeting
A Clinical Analysis of Adult Patients with Autoimmune- and Infection-Associated Hemophagocytic Lymphohistiocytosis
Min W. So¹, Bon S. Koo¹, You J. Kim¹, Yong-G Kim¹, Wook J. Seo², Chang-K Lee¹ and Bin Yoo¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ²Internal Medicine, Seoul Veterans Hospital, Seoul, South Korea
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare but potentially life-threatening disease. Secondary HLH is associated with various clinical conditions, including infections, malignancies, and autoimmune diseases.…
Abstract Number: 1063 • 2012 ACR/ARHP Annual Meeting
Dysfunction of Natural Killer and Natural Killer T Cells in Patients with Adult Onset Still’s Disease
Young-Nan Cho¹, Sung-Ji Lee¹, Tae-Jong Kim², Hye-Mi Jin¹, Dong-Jin Park², Seung-Jung Kee³ and Yong-Wook Park¹, ¹Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ²Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ³Laboratory Medicine, Chonnam National University Medical School and Hospital, Gwangju, South Korea
Background/Purpose: Adult onset Still’s disease (AOSD) is an uncommon systemic inflammatory disorder of unknown etiology. Natural killer (NK) cell dysfunction is frequently observed in some…
Abstract Number: 191 • 2012 ACR/ARHP Annual Meeting
Analysis of Genes Involved in Autoinflammatory Diseases in Adult Onset Still’s Disease
Emma Garcia-Melchor¹, Dolors Grados², Eva Gonzalez-Roca¹, Elena Riera³, Manel Juan¹, Jordi Yagüe¹, Juan Ignacio Aróstegui¹, Javier Narváez⁴ and Alejandro Olivé⁵, ¹Immunology Department, Hospital Clinic Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ³Rheumatology Department, Hospital Mutua de Terrassa, Terrassa, Spain, ⁴Rheumatology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁵Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Adult Onset Still’s Disease (AOSD) is a systemic inflammatory disease characterized by fever, skin rash, articular involvement, lymphadenopathy, hepatosplenomegaly and serositis. Due to the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].